Relevant bibliographies by topics / Lassa fever

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Lassa fever'

Author: Grafiati
Published: 4 June 2021
Last updated: 30 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Lassa fever.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Lassa fever"

1

McCormick, Joseph B., Isabel J. King, Patricia A. Webb, Curtis L. Scribner, Robert B. Craven, Karl M. Johnson, Luanne H. Elliott, and Rose Belmont-Williams. "Lassa Fever." New England Journal of Medicine 314, no. 1 (January 2, 1986): 20–26. http://dx.doi.org/10.1056/nejm198601023140104.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Coyle, Amanda L. "Lassa fever." Nursing 46, no. 7 (July 2016): 69–70. http://dx.doi.org/10.1097/01.nurse.0000482873.70955.7b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Roberts, Amy, and Charles Kemp. "Lassa Fever." Journal of the American Academy of Nurse Practitioners 14, no. 7 (July 2002): 289–90. http://dx.doi.org/10.1111/j.1745-7599.2002.tb00127.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Banatvala, J. E. "Lassa fever." BMJ 293, no. 6557 (November 15, 1986): 1256–57. http://dx.doi.org/10.1136/bmj.293.6557.1256.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bannister, B. "Lassa fever." BMJ 302, no. 6768 (January 12, 1991): 114. http://dx.doi.org/10.1136/bmj.302.6768.114-b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Asogun, Danny A., Stephan Günther, George O. Akpede, Chikwe Ihekweazu, and Alimuddin Zumla. "Lassa Fever." Infectious Disease Clinics of North America 33, no. 4 (December 2019): 933–51. http://dx.doi.org/10.1016/j.idc.2019.08.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fisher-Hoch, Susan P., and Joseph B. McCormick. "Lassa fever vaccine." Expert Review of Vaccines 3, no. 2 (April 2004): 189–97. http://dx.doi.org/10.1586/14760584.3.2.189.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bhadelia, Nahid. "Understanding Lassa fever." Science 363, no. 6422 (January 3, 2019): 30. http://dx.doi.org/10.1126/science.aav8958.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wiwanitkit, Viroj. "Lassa viral hemorrhagic fever." Medical Journal of Dr. D.Y. Patil Vidyapeeth 13, no. 1 (2020): 28. http://dx.doi.org/10.4103/mjdrdypu.mjdrdypu_144_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Yun, Nadezhda E., and David H. Walker. "Pathogenesis of Lassa Fever." Viruses 4, no. 10 (October 9, 2012): 2031–48. http://dx.doi.org/10.3390/v4102031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Lassa fever"

1

Wilkinson, Ann. "The process and practice of diagnosis : innovations in diagnostics for Lassa fever in Sierra Leone." Thesis, University of Sussex, 2013. http://sro.sussex.ac.uk/id/eprint/47209/.

Full text
Abstract:
This thesis is about the process and practice of diagnosis and the implications of new diagnostic technologies in low resource settings. As a setting and a disease which has seen significant investment in diagnostics, Lassa fever in Sierra Leone has been selected as a case study to examine these themes. In this thesis, 'new diagnostic technologies' refers to laboratory-based diagnostics which are fast, reliable, accurate and can be used in low income settings. The starting point of this thesis is a narrative surrounding such technologies which suggests that they will revolutionise low income healthcare settings by allowing accurate scientific diagnosis in places where it was not possible before. Various perspectives on diagnosis are examined and some limitations are identified in relation to their accounts of diagnostic process, context, practice and technology. To explore the case, aspects of science and technology studies, the sociology of scientific knowledge and medical anthropology are combined. A multi-sited ethnography of Lassa fever diagnosis was conducted in three settings: a rural village, a laboratory and the wards of a hospital. Documents were reviewed and interviews conducted with key actors and ex-Lassa fever patients. Analysis focused on framings (partial and subjective interpretations), narratives (persuasive storylines which make use of particular framings) and practice in relation to Lassa fever and the development of technology for its diagnosis. Assumptions about the disease, diagnostics and the process of diagnosis are identified and the conclusion considers how they compare with practice in each setting. This thesis argues that diagnosis is a complex negotiated process and that new diagnostics represent only one aspect of that process. Thus, they are not a ‘silver bullet' to transform low resource healthcare contexts. In particular, ‘improved' diagnostics do not always have the expected impacts, sometimes even introducing complexity and uncertainty. In challenging narratives about diagnostics, this thesis provides an alternative, practice-based, approach to thinking about diagnostics and innovations in health systems; this approach acknowledges the importance, and complexity, of the diverse contexts which shape innovations and technology use.
APA, Harvard, Vancouver, ISO, and other styles
2

Krasilnikova, Lydia A. "Metagenomic investigation of co-infections of Ebola virus disease and Lassa fever patients." Thesis, Massachusetts Institute of Technology, 2016. http://hdl.handle.net/1721.1/106113.

Full text
Abstract:
Thesis: M. Eng. in Computer Science and Molecular Biology, Massachusetts Institute of Technology, Department of Electrical Engineering and Computer Science, 2016.
Cataloged from PDF version of thesis.
Includes bibliographical references (page 37).
Sequencing followed by metagenomic analysis is an extremely promising method for broad, unbiased disease profiling of patients for disease surveillance and diagnosis. Here, we use two popular metagenomics tools in union, k-mer-based Kraken with reads and BLAST- and LCAbased MEGAN with assembled contiguous sequence. We analyze sequence from 463 febrile and afebrile patients from Sierra Leone before and during the 2014 Ebola virus outbreak. We find that co-infection with malaria is correlated with increased survival of Ebola virus patients, from 18% survival rate to 53%. We also explore the utility of and emphasize the need for both positive and negative controls to distinguish and remove noise and contaminants from real signal, especially to keep up with increasing sensitivity in sequencing.
by Lydia A. Krasilnikova.
M. Eng. in Computer Science and Molecular Biology
APA, Harvard, Vancouver, ISO, and other styles
3

Baillet, Nicolas. "Pathologie comparée de la fièvre de Lassa chez le singe cynomolgus : mécanismes pathogéniques précoces, réponses immunitaires et marqueurs d’infection." Thesis, Lyon, 2018. http://www.theses.fr/2018LYSE1307.

Full text
Abstract:
Le virus Lassa entraine une fièvre hémorragique endémique en Afrique de l’Ouest et représente un problème de santé publique. Les connaissances sur la pathogénèse et les réponses immunitaires associées à la maladie sont partielles. Nous avons suivi les paramètres pathologiques, virologiques et immunologiques associés aux infections létales et non létales du LASV chez le singe cynomolgus. Le tableau clinique a été caractérisé par une dépression, une anorexie, une perte de poids et une asthénie chez les animaux survivants, tandis que ces mêmes symptômes ont été accompagnés de fièvre, de difficultés respiratoires et d’épistaxis chez les animaux infectés par une dose létale. Seuls ces derniers ont montré une perturbation des paramètres de coagulation, une rhabdomyolyse et une hausse des marqueurs de lésions rénales. Nous avons observé un tropisme radicalement différent en fonction de la sévérité de la maladie, avec une dissémination virale dans les organes plus importante et plus rapide chez les animaux décédés, la présence de particules infectieuses plus nombreuses et des modifications anatomopathologiques plus sévères. Une réponse immunitaire innée et adaptative précoce et puissante a été associée avec le contrôle de l’infection et la survie tandis que les infections fatales ont été caractérisées par une réponse inflammatoire ressemblant au choc septique, une défaillance de la réponse immunitaire ainsi qu’une réplication virale incontrôlée. Cette étude permet d’améliorer nos connaissances de la pathogénèse de la fièvre de Lassa et d’apporter des marqueurs d’infection prédictifs de la maladie
Lassa virus causes a hemorrhagic fever endemic in West Africa and represents a threat for civilians. The pathogenesis and the immune responses associated with the disease are poorly understood. We followed pathological, virological and immunological parameters associated with fatal and non-fatal Lassa virus infection in the cynomolgus monkey. The clinical picture was characterized by depression, anorexia, weight loss and asthenia in survivors whereas the same symptoms were supported by fever, respiratory difficulties and epistaxis in animals infected with the lethal dose. Only fatalities have shown coagulation parameters dysfunction, rhabdomyolysis and an increase of renal function markers. We observed a different viral tropism in a function of the disease severity, with viral dissemination in organs that was more important and faster in fatalities, the appearance of numerous infectious particles number and more severe pathologic changes. Early and robust innate and adaptive immune response has been associated with the control of infection and recovery whereas fatal infections were characterized by a sepsis like inflammatory response, defective immune response as well as uncontrolled viral replication. This study sheds light on the pathogenesis of Lassa fever and reveals infection markers predictive of the disease outcome
APA, Harvard, Vancouver, ISO, and other styles
4

Cedergren, Linda. "Expression of recombinant protein including an His-tag to facilitate purification for diagnosis of CCHF and Lassa Viruses." Thesis, Uppsala University, Department of Medical Biochemistry and Microbiology, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-7064.

Full text
Abstract:

Abstract

Crimean-Congo Hemorrhagic Fever virus (CCHF) and Lassa virus are giving sources illness to humans. In addition to zoonotic transmission, CCHF and Lassa virus can spread from person to person. After a short incubation period, CCHF and Lassa virus infections are characterized by a sudden onset of high fever, chills, headache and cough just like flu. Even some people are vomiting and have diarrhoea. After a few days of illness hemorrhagic manifestations occur. Treatment options for CCHF and Lassa viruses are limited, and there is no vaccine available for use in humans. The purpose of the present study was to produce recombinant nucleocapsid protein of Lassavirus and CCHF virus including an aminoterminal His-tag by a Semliki Forest Virus Replicon (pSFV 4.2). The recombinant proteins are planned to be used in future development of diagnostic methods.

APA, Harvard, Vancouver, ISO, and other styles
5

Duvignaud, Alexandre. "Aspects cliniques, biologiques et pronostiques de la fièvre de Lassa en contexte endémo-épidémique en Afrique de l’Ouest : exemple du Nigeria." Thesis, Bordeaux, 2020. http://www.theses.fr/2020BORD0254.

Full text
Abstract:
La fièvre de Lassa, maladie endémique à recrudescence épidémique saisonnière, est avec 300 000 cas et 5000 décès annuels estimés à travers toute l’Afrique de l’Ouest considérée comme une priorité en terme de recherche. Ces dernières années, le Nigeria a rapporté un nombre de cas annuel en constante augmentation, dépassant désormais le millier. Mais cinquante ans après sa découverte, les connaissances sur la maladie restent parcellaires et la recherche clinique peu structurée. L’efficacité du seul traitement recommandé, la ribavirine, est aujourd’hui remise en cause. Il apparait donc urgent de pouvoir disposer de données actualisées, précises et fiables sur la maladie, son cours évolutif, sa prise en charge, son pronostic et les facteurs qui y sont associés. Il est également important que les malades qui en souffrent puissent avoir accès à un standard de soins optimisé. Il est enfin indispensable de développer les capacités de recherche clinique en zone d’endémie.Dans cette thèse, nous faisons une synthèse des connaissances accumulées sur la fièvre de Lassa depuis sa découverte en 1969. Puis nous exposons les raisons qui nous ont conduits à mettre en place un programme de réponse et de recherche sur la fièvre de Lassa. Nous expliquons la démarche suivie pour renforcer le standard de soins et mettre en place une plateforme de recherche clinique en collaboration avec l’un des principaux centres de prise en charge de la fièvre de Lassa au Nigeria. Nous présentons les premiers résultats de l’étude de cohorte prospective LASCOPE qui inaugura ce programme.Entre avril 2018 et mars 2020, ce sont 534 patients atteints de fièvre de Lassa prouvée par RT-PCR qui ont été pris en charge dont 77 (14,4%) sont décédés. 510 participants ont été inclus. Parmi eux on dénombrait 258 hommes et 252 femmes ; 84 étaient des enfants. Le délai médian entre l’apparition des symptômes et l’admission était de 8 jours (IIQ 7-13). A l’admission, 37,8% avaient une valeur de Ct de la RT-PCR du gene GPC du virus de Lassa <30. Entre l’admission et la fin du suivi, 120 (26,5%) ont atteints un score NEWS2 ≥7, 67(13,5%) un stade KDIGO ≥2 et 41 (8,0%) ont été dialysés. Tous ont reçu de la ribavirine pendant une durée médiane de 10 jours (IIQ 9-13). 62 (12,2%) sont décédés (57 [13,4%] adultes, 5 [6,0%] enfants. Le délai médian entre l’admission et le décès était de 3 jours (IIQ 1-6). Les caractéristiques suivantes à l’admission étaient associées à la mortalité en analyse multivariable : l’âge ≥ 45 ans (Odds Ratio ajusté [aOR] 16,30 [IC95% 5,31-50,30]), un score NEWS2 ≥7 (aOR 4,79 [IC95% 1,75-13,10]), un stade KDIGO ≥2 (aOR 7,52 [IC95% 2,66-21,20]), une valeur d’ALAT ≥ 3 fois la limite supérieure de la normale (aOR 4,96 [IC95% 1,69- 14,60]) et une valeur de Ct de la RT-PCR Lassa <30 (aOR 4,65 [IC95% 1,50-14,50]). Ces résultats devraient s’avérer utiles pour la conception de futurs essais cliniques mais aussi pour l’actualisation des recommandations de prise en charge de la maladie. Le cadre de cette étude de cohorte nous a également permis de documenter et décrire une présentation atypique de la maladie, sous la forme d’une paraparésie d’apparition retardée. Cette observation originale vient compléter le spectre évolutif des manifestations neurologiques de la fièvre de Lassa.Deux études complémentaires sont nichées dans la cohorte LASCOPE, portant respectivement sur la pharmacocinétique de la ribavirine telle qu’employée dans le traitement de la fièvre de Lassa et sur la physiopathologie de l’atteinte cardio-circulatoire pouvant survenir au cours de la maladie. Le recrutement dans ces études nichées est toujours en cours.Enfin, un essai clinique de phase II évaluant la pharmacocinétique, la sécurité et la tolérance d’un nouvel antiviral, le favipiravir, pour le traitement de la fièvre de Lassa est également en cours de mise en place sur deux sites au Nigeria dont celui avec lequel nous collaborons
Lassa fever, an endemic disease with seasonal epidemic recrudescence, is considered to be responsible for 300 000 cases and 5000 death each year throughout Western Africa. As such, it has been listed as a priority for research. Over the past few years, Nigeria reported the highest and ever increasing number of cases, now exceeding a thousand per year. However, fifty years after the discovery of the disease, our knowledge is still limited and clinical research capacities remained poorly developed. The efficacy of the only available treatment, ribavirin, is still to be assessed. Hence, there is a need for up to date and reliable data on the disease course, management, mortality and prognostic factors. It is also of paramount importance that the patients suffering from Lassa fever could gain access to an optimised standard of care. Lastly, clinical research capacities need to be developed urgently in endemic areas.In this thesis, we review the knowledge gathered on Lassa fever from its discovery in 1969 till date. Then, we explain the reasons that led us to set up a response and research program on Lassa fever, as well as our approach to reinforce the standard of care and build a clinical research platform in collaboration with one of the main Lassa treatment centres in Nigeria. Next, we present the first results of the LASCOPE cohort study which represent the cornerstone of our program.From April 2018 to March 2020, 534 patients with RT-PCR proven Lassa fever were followed-up of whom 77 died (14.4%). 510 participants were enrolled in the cohort: 258 men and 252 women, 84 being children. The median delay between the symptoms onset and admission was 8 days (IQR 7-13). On admission, 37.8% had a Lassa RT-PCR Ct value <30. From admission to end of follow-up, 120 (26.5%) had a NEWS2 ≥7, 67(13.5%) had a KDIGO ≥2, and 41 (8.0%) underwent dialysis. All of them received ribavirin therapy with a median duration of 10 days (IQR 9-13). 62 (12.2%) died (57 [13.4%] adults, 5 [6.0%] children. The median delay between admission and death was 3 days (IQR 1-6). The following characteristics on admission were independently associated to mortality: age ≥ 45 years (adjusted Odds Ratio [aOR] 16.30 [95%CI 5.31-50.30]), NEWS2 ≥7 (aOR 4.79 [95%CI 1.75-13.10]), KDIGO ≥2 (aOR 7.52 [95%CI 2.66-21.20]), ALAT ≥ 3 times the upper limit of normal range (aOR 4.96 [95%CI 1.69- 14.60]), a Lassa RT-PCR Ct value <30 (aOR 4.65 [95%CI 1.50-14.50]). Those results will be helpful for the conception of future therapeutic clinical trials as well as for updating existing management guidelines. The framework of this cohort also gave us the opportunity to describe an unusual presentation of the disease, namely delayed paraparesis. This original observation add to the evolving knowledge regarding the spectrum of Lassa fever-related neurological manifestations.Two complementary studies are nested in the LASCOPE cohort, concerning the pharmacokinetics of ribavirin, as it is used for the treatment of Lassa fever, as well as the pathophysiology of cardiovascular dysfunction that can occur during Lassa fever. Inclusions in these nested studies is still ongoing.Finally, an upcoming phase II clinical trial evaluating the pharmacokinetics, security and tolerability of a novel antiviral drug, favipiravir, for the treatment of Lassa fever is currently being prepared in two Nigerian sites, including the one we are collaborating with
APA, Harvard, Vancouver, ISO, and other styles
6

Qi, Xiaoxuan. "Structural and functional studies of novel mechanisms of Lassa fever virus nucleoprotein in immune suppression, viral RNA transcription and replication." Thesis, University of St Andrews, 2012. http://hdl.handle.net/10023/3601.

Full text
Abstract:
Lassa fever virus is one of the most dangerous viruses of arenaviridae family, causing more than 500,000 infections per year in Africa. The fatality rate for hospitalized patients is as high as 20%. Due to the high fatality and lack of efficient licensed drugs and vaccines to treat and prevent, Lassa fever virus is classified as a Category A priority pathogen and biosafety level-4 agent by the Centers for Disease Control and Prevention of the USA. Cases were also found in the Americas and European countries, highlighting its potency to be a bioterrorism weapon. Like other areanaviruses, Lassa virus has developed a unique interferon suppression mechanism to evade from the host immune system, in which Lassa nucleoprotein plays the key role. To understand the LASV nucleoprotein functions, we tried to determine the first arenaviral nucleoprotein structure, LASV nucleoprotein. The LASV nucleoprotein (NP) was overexpressed and purified. The NP protein was crystallized and the structure was determined to 1.80 Å resolution. The crystals belong to space group P3, with the unit cell parameters a = b = 177.16 Å, c = 56.49 Å, α= β= 90° and γ= 120°. The LASV NP structure contains two domains, which are not similar to any reported viral nucleoprotein structures. The N-terminal domain has a novel structure with a cavity, which we proposed for cap binding, and the C-terminus is a 3'-5' ribonuclease, which is responsible for suppressing interferon production. To characterize the possible interaction between NP and other arenaviral protein, we also overexpressed and purified LASV Z. Interestingly, both NP and Z proteins have two forms and the purified NP protein and monomeric Z protein bind RNA. It is surprising that only the oligomeric Z protein interacts with NP protein but the monomeric Z protein does not as determined by Isothermal Titration Calorimetry (ITC). Our studies have reported the first arenaviral nucleoprotein structure, revealed the novel mechanism for the cap binding and immune suppression, which set up a platform for the development of novel drugs and vaccines to treat deadly arenaviral infections.
APA, Harvard, Vancouver, ISO, and other styles
7

Port, Julia Rebecca [Verfasser], Lars [Akademischer Betreuer] Redecke, and Tamás [Akademischer Betreuer] Laskay. "Implications of T-lymphocyte homing in Lassa fever pathogenesis and transmission / Julia Rebecca Port ; Akademische Betreuer: Lars Redecke, Tamás Laskay." Lübeck : Zentrale Hochschulbibliothek Lübeck, 2021. http://d-nb.info/1228017913/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wallat, Gregor D. "Structure determination of the major outer membrane protein from Campylobacter jejuni, &, Structural and functional studies of the endonuclease from Lassa virus." Thesis, University of St Andrews, 2015. http://hdl.handle.net/10023/8112.

Full text
Abstract:
The major outer membrane protein, MOMP, is the main protein in the outer membrane of pathogenic Campylobacter bacteria. Infection with Campylobacter is the principle cause of severe enteritis and untreated may result in non-trauma related paralysis. Studies have shown, that MOMP can act as antigen and thus has the potential to provide protection by induced humoral immunity. In our study, we expressed recombinant MOMP in Escherichia1coli, developed an alternative method to extract the outer membrane protein from its lipid environment and solved and characterised its crystal structure. The information acquired through these structural studies sheds new light on the structural characteristics of this important membrane protein. The West-African Lassa virus can cause deadly haemorrhagic fever. Lassa virus only possesses five proteins, which are synergistically responsible for the virus' life cycle, and virulence. The way in which the individual proteins act with one another and with host cell proteins is not fully understood. The polymerase L is the largest of the five proteins and has multiple functions. In this study, we first divided the L protein into different domains and tested their recombinant expression in Escherichia1coli. For first time, we solved the crystal structure of the putative endonuclease domain of Lassa virus and validated its endonucleolytic function by means of RNA digestion assays and alanine point mutations.
APA, Harvard, Vancouver, ISO, and other styles
9

Offor, Joy. "Lassa fever epidemic outbreak causing maternal mortality on pregnant women : A statistical and systematic review on prevalence and occurrence of maternal mortality in Nigeria." Thesis, Södertörns högskola, Institutionen för naturvetenskap, miljö och teknik, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:sh:diva-42026.

Full text
Abstract:
Introduction/background: Epidemics of infectious diseases (ID) are re-occurring now more often and spreads faster into many different parts of the world due to globalization. The increasing evidence of climate change and man-made events have shown impacts to increase the emergency and re-emerging of animal- borne IDs. Studies claims that background factors of these IDs are biological, environmental and human-lifestyle related changes. The pathogen Lassa fever virus (LASV) is a zoonotic organismthat circulates in rodent reservoirs, and the animal´s hosts are rodent species (rats) of the genus Mastomys natalensis. Mastomys natalensis is primarily the reservoir species of the animal-borne disease of Lassa fever (LF) which is most prevalent in west Africa, particularly in Nigeria. Lassa fever (LF) has limited information with under-documented cases, its health effect on pregnant women especially in Nigeria is within the rural areas of Edo, Ondo, Delta, Ebony, Bauchi, Taraba and Plateau states where maternal mortalities are higher.  Aim: The overarching aim of this thesis is to analyse and discuss the health effects of Lassa fever occurrence and outcomes on pregnant women in Nigeria, with emphasis on the maternal mortality and fatality during pregnancy. Method: A statistical and systematic review was performed from retrospective studies of case series, case-control, observational and cohort studies of patients in Nigeria (pregnant women with gestation ages of pregnancy from 2 weeks –32 weeks) that tested positive to LASV. Publication status and publication date was applied for the inclusion of respective studies by electronic searches via Web of Science, Google scholar, MEDLINE and PubMed. Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines (PRISMA) was used to illustrate the flow of relevant articles in my study. R-commander and R-Studio software was used to analyze the data and to find the causal significant relationship between LF and maternal mortality using “Linear regression and linear model plot”. Result: The total number of full-text and Peer-view publications on Lassa fever virus cases was 1 609 articles. 94 articles out of the 1 609 articles were eligible for full text revision. Exclusion criteria finally yielded 6 studies that were relatively relevant to my study. However, 3 out of the 6 articles were statistically reviewed to know the influence of Lassa fever and the risk of maternal mortality during pregnancy.  Conclusion: Lassa fever occurrence have significantly shown potential increase in the severity of maternal mortality, and is predominant among pregnant women from 39 - 45 years old in Nigeria especially within the risk endemic areas of Ondo, Edo, Ebony and Bauchi states showing significant long-term diseases on LF affected pregnant women, such as encephalopathy, acute kidney dysfunction and acute kidney failure that leads to further health problems or complications like coma and sensorineural deafness.
APA, Harvard, Vancouver, ISO, and other styles
10

Schaeffer, Justine. "Étude in vitro et ex vivo de la réponse des cellules dendritiques à l’infection par le virus Lassa." Thesis, Lyon, 2018. http://www.theses.fr/2018LYSE1249/document.

Full text
Abstract:
Le virus Lassa (LASV) induit une fièvre hémorragique chez l’homme et est responsable de 3 000 à 5 000 décès par an. Aucun vaccin ou traitement efficace contre LASV n’est disponible, et les mécanismes de pathogenèse de la fièvre de Lassa sont encore mal compris. Des études chez l’homme et le primate suggèrent que la réponse interféron de type I (IFN-I) et de la réponse T sont critiques pour la survie de l’hôte. Nous nous sommes intéressés à la réponse des cellules dendritiques (DC) à LASV, car elles peuvent à la fois produire des IFN-I et induire la réponse T. Nous avons étudié les DC plasmacytoïdes (pDC), spécialisées dans la réponse IFN-I, et les DC myéloïdes (mDC), présentatrices d’antigènes. Nous avons montré que les pDC et les mDC ne sont pas productivement infectées par MOPV et LASV. Les pDC produisent des quantités importantes d’IFN-I en réponse à MOPV, mais pas à LASV. Les mDC sont activées et produisent des IFN-I en réponse à MOPV mais aussi à LASV. Cependant, seules les mDC infectées par MOPV sont capables d’activer des lymphocytes T. De plus, la présence de lymphocytes T inhibe complètement l’activation des mDC infectées par LASV. Ces différences entre les mDC infectées par MOPV et LASV dépendent de la nucléoprotéine de LASV, qui est connue pour ses propriétés immunosuppressives, mais aussi de la glycoprotéine. En résumé, nous avons obtenu des différences de réponse à l’infection par MOPV ou LASV chez les pDC et les mDC. Ces cellules pourraient avoir un rôle essentiel in vivo dans la réponse globale à LASV, et donc dans l’issue de la fièvre de Lassa
Lassa virus (LASV) is responsible for a viral haemorrhagic fever in humans and the death of 3,000 to 5,000 people every year. There is currently no vaccine or treatmentavailable against LASV, and its pathogenesis is not completely understood yet. According to studies on humans and primates, type I interferon (IFN-I) and T cell responses appear to be critical for the host. We studied the response of dendritic cells (DC) to LASV, as DC are involved in both IFN-I production and T cell activation. We compared the response of primary human DC to LASV and Mopeia virus (MOPV), which is similar to LASV, but non-pathogenic.We focused on plasmacytoid DC (pDC), specialized in IFN-I production, and myeloid DC (mDC), specialized in antigen presentation. We showed that neither pDC nor mDC were productively infected by LASV and MOPV. pDC infected with MOPV produced large amounts of IFN-I, whereas pDC infected with LASV did not. mDC produced substantial amounts of IFN-I in response to both LASV and MOPV. However, only MOPV-infected mDC were able to activate T cells. More surprisingly, coculture with T cells completely inhibited the activation of LASV-infected mDC. These differences between LASV- and MOPV-infected mDC were mostly due to LASV nucleoprotein, which has major immunosuppressive properties, but the glycoprotein was also involved. Overall, these results showed differences in pDC and mDC response to MOPV and LASV. Therefore, both pDC and mDC may be important for the global response to LASV in vivo, and play a role in the outcome of Lassa fever
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Lassa fever"

1

The Lassa ward. London: Bantam Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

The Lassa Ward: One man's fight against one of the world's deadliest diseases. New York: St. Martin's Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lassa Fever. MDPI, 2020. http://dx.doi.org/10.3390/books978-3-03936-610-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Donaldson, Ross. Lassa Ward. Transworld Publishers Limited, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Donaldson, Ross. Lassa Ward. Penguin Random House, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schechter, Marcos. Viral Hemorrhagic Fevers (Ebola, Lassa, Hantavirus). Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199976805.003.0066.

Full text
Abstract:
Viral hemorrhagic fever (VHF) designates diseases caused by enveloped, single-stranded RNA viruses belonging to the families Ebola, Lassa, Hantavirus, and yellow fever. Unifying features include fever, capillary leak, and coagulation defects. These viruses can affect all organ systems; transmission occurs via contact with rodent excretions, either by ingestion or through mucosa or non-intact skin. Aerosolized rodent urine and saliva are also infectious. Person-to-person spread has been documented in Lassa and Machupo viruses, both by direct contact with bodily fluids and by airborne transmission. Thrombocytopenia is a common laboratory finding. Most acutely ill patients have high concentrations of virus in the blood as measured by polymerase chain reaction assay. Clinical differentiation between the various causes of VHF is difficult. Care is supportive. No antiviral drug, including ribavirin, has activity against these viruses. Most of these diseases do not occur naturally in the United States; however, some are considered viable for bioterrorism.
APA, Harvard, Vancouver, ISO, and other styles
7

Donaldson, Ross. Lassa Ward: One Man's Fight Against One of the World's Deadliest Diseases. Transworld Publishers Limited, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Donaldson, Ross. Lassa Ward: One Man's Fight Against One of the World's Deadliest Diseases. St. Martin's Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Donaldson, Ross. The Lassa Ward: One Man's Fight Against One of the World's Deadliest Diseases. St. Martin's Griffin, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Publications, ICON Health. Lassa Fever: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References. Icon Health Publications, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Lassa fever"

1

McCormick, J. B., and S. P. Fisher-Hoch. "Lassa Fever." In Current Topics in Microbiology and Immunology, 75–109. Berlin, Heidelberg: Springer Berlin Heidelberg, 2002. http://dx.doi.org/10.1007/978-3-642-56029-3_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Davis, James W., Dana Forman, La Scienya M. Jackson, James W. Davis, Javier Garau, David N. O’Dwyer, Elisa Vedes, et al. "Lassa Fever." In Encyclopedia of Intensive Care Medicine, 1324. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_1816.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gooch, Jan W. "Lassa Fever." In Encyclopedic Dictionary of Polymers, 903. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-6247-8_14091.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fisher-Hoch, S. P., and J. B. McCormick. "Pathophysiology and Treatment of Lassa Fever." In Current Topics in Microbiology and Immunology, 231–39. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71726-0_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

McCormick, J. B. "Epidemiology and Control of Lassa Fever." In Current Topics in Microbiology and Immunology, 69–78. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71726-0_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Imanov, Elbrus, and Fidelis Jumare Asengi. "Artificial Intelligence for Lassa Fever Diagnosis System." In Advances in Intelligent Systems and Computing, 540–47. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-64058-3_67.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bausch, Daniel G., and James N. Mills. "Arenaviruses: Lassa Fever, Lujo Hemorrhagic Fever, Lymphocytic Choriomeningitis, and the South American Hemorrhagic Fevers." In Viral Infections of Humans, 147–71. Boston, MA: Springer US, 2014. http://dx.doi.org/10.1007/978-1-4899-7448-8_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Salvato, Maria S., Igor S. Lukashevich, Sandra Medina-Moreno, and Juan Carlos Zapata. "Diagnostics for Lassa Fever: Detecting Host Antibody Responses." In Methods in Molecular Biology, 79–88. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6981-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Auperin, David D. "Construction and Evaluation of Recombinant Virus Vaccines for Lassa Fever." In The Arenaviridae, 259–80. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-3028-2_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Qi, Xiaoxuan, Wenjian Wang, Haohao Dong, Yuying Liang, Changjiang Dong, and Hinh Ly. "Expression and X-Ray Structural Determination of the Nucleoprotein of Lassa Fever Virus." In Methods in Molecular Biology, 179–88. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6981-4_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Lassa fever"

1

Akhuemokhan, OC, J. Ehiemua, DI Adomeh, I. Odia, SC Olomu, B. Becker-Ziaja, CT Happi, et al. "G311 Lassa fever and convulsions associated with fever: A case-control study." In Royal College of Paediatrics and Child Health, Abstracts of the Annual Conference, 24–26 May 2017, ICC, Birmingham. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2017. http://dx.doi.org/10.1136/archdischild-2017-313087.304.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Oluwole, Akinola Solomon, and Thembinkosi Nkonyana. "Forecasting Lassa Fever Outbreak Progression with Machine Learning." In 2022 International Conference on Electrical, Computer, Communications and Mechatronics Engineering (ICECCME). IEEE, 2022. http://dx.doi.org/10.1109/iceccme55909.2022.9987787.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Abdullahi, Mohammed Baba, Umar Chado Doko, and Mamman Mamuda. "Sensitivity analysis in a Lassa fever deterministic mathematical model." In INTERNATIONAL CONFERENCE ON MATHEMATICS, ENGINEERING AND INDUSTRIAL APPLICATIONS 2014 (ICoMEIA 2014). AIP Publishing LLC, 2015. http://dx.doi.org/10.1063/1.4915683.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

MAIA, DIEGO OLIVEIRA, JÚLIA DE HOLLANDA CELESTINO, LORENA AGRA RAMOS, EMANUEL VICTOR DA SILVA LIMA, and TATIANA PASCHOALETTE RODRIGUES BACHUR. "FEBRE DE LASSA: TERIA ESSA DOENÇA POTENCIAL PANDÊMICO?" In II Congresso Nacional de Microbiologia Clínica On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/ii-conamic/16.

Full text
Abstract:
Introdução: A febre de Lassa (FL) é uma infecção hemorrágica causada por um Mammarenavirus – o LASV – vírus de RNA de fita simples da família Arenaviridae. O principal reservatório do LASV é o camundongo Mastomys natalensis, comum no continente africano. A maioria dos casos são assintomáticos, porém a FL pode manifestar-se clinicamente através de febre, mal-estar, tosse, dor no peito, cólicas abdominais, vômitos, diarreia e dor de garganta. Casos graves evoluem com manifestações hemorrágicas e elevada taxa de mortalidade. A transmissão da infecção pode ocorrer por meio do contato com urina, fezes ou saliva do roedor ou mediante contato direto com fluidos corporais de indivíduos infectados ou superfícies contaminadas. Objetivo: Realizar uma levantamento bibliográfico acerca da epidemiologia da febre de Lassa e sua possível capacidade de disseminação global. Métodos: Foi realizada uma pesquisa bibliográfica nas bases de dados MEDLINE e EMBASE, por meio dos descritores “lassa fever” e “epidemiology”, combinados pelo operador booleano AND. A partir de critérios de inclusão e exclusão pré-estabelecidos, foram selecionados seis artigos para compor este trabalho. Resultados: A FL se apresenta como uma doença endêmica na África Ocidental, com comportamento sazonal, tendo incremento de casos no início e no final do período chuvoso. O primeiro caso de FL foi relatado na Nigéria na década de 1960 causando, desde então, vários surtos nesse país e em países adjacentes, com taxas de mortalidade de até 50%. Contudo, a infecção já foi descrita fora da área endêmica, tendo sido relatados pelo menos 35 casos exportados para países como Estados Unidos, Reino Unido, Alemanha e Japão, no período de 1969 a 2020, o que tem sido associado às atividades humanas de comércio e migração. Até o momento, apenas um caso de transmissão autóctone em área indene foi relatado em consequência de casos importados da África Ocidental. Conclusão: A febre de Lassa apresenta-se como uma doença endêmica no continente africano, porém com capacidade disseminativa para outras regiões do globo, o que torna necessário que haja maior vigilância epidemiológica para reconhecimento dos casos, especialmente os assintomáticos, que representam a maioria dos acometidos, visto que a doença pode ser transmitida entre indivíduos infectados.
APA, Harvard, Vancouver, ISO, and other styles
5

Lewis, R. M., P. B. Jahrling, B. P. Griffin, and T. M. Cosgriff. "THE EFFECTS OF HEMORRHAGIC FEVER VIRUS INFECTION OF ENDOTHELIAL CELLS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643352.

Full text
Abstract:
Pichindé viral infection of strain 13 guinea pigs is a model for Lassa fever virus in humans. Infected animals show impaired platelet function and altered coagulation parameters. Human endothelial cells and the human endothe1ia1-1 ike cell line, EA926, were infected with Pichinde virus. Following infection, cultures were monitored by phase contract microscopy for cytopathic effect (CPE). Assays of supernatant were used to document viral growth and to measure those endothelial-produced components that might affect hemostasis. In addition, the cells were stimulated with phorbol ester (PMA), which stimulates the production of prostacyclin. Infection showed no noticeable effect on the endothelial cells or EA926 cells which were untreated with PMA. PHA-treated EA926 cells were subject to CPE. Factor VIII antigen was not significantly affected by viral infection, PMA treatment, or endotoxin exposure. The production of PGFl, measured as an estimate of prostacyclin synthesis, was dependent on the concentration of stimulating PMA. Infected cultures showed decreased responsiveness to PMA stimulation when infected by increasing concentrations of Pichindé. The most noticeable effect was noted when cultures were infected with a multiplicity of infection of 0.1 and 100 ng/ml PMA. Thromboxane B2 an estimate of thromboxane A2, showed no significant change. No detectable leukotriene C4 was produced and no significant change in leukotriene B4 was measured. The decreased prostacyclin production by the infected endothelial cells may indicate a role for the endothelium in the hemorrhagic syndrome that accompanies some viral diseases.
APA, Harvard, Vancouver, ISO, and other styles
6

Cosgriff, T. M., P. G. Canonico, L. Hodgson, D. Parrish, T. Chapman, J. W. Huggins, Z.-J. Gong, L.-B. Xiang, and C.-H. Hsiang. "RIBAVIRIN: STUDIES OF THE EFFECTS OF THE ANTIVIRAL DRUG ON PLATELET FUNCTION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644545.

Full text
Abstract:
Ribavirin is a broad-spectrum antiviral drug which is presently undergoing testing in patients with AIDS-related complex. It has also been shown to have activity against respiratory syncytial virus, Sicilian sandfly fever virus, influenza A and B viruses, as well as several hemorrhagic fever viruses. It has proved effective in clinical trials in Lassa fever and shows promise as therapy for hemorrhagic fever with renal syndrome. Because platelet dysfunction may contribute significantly to hemostatic impairment in viral hemorrhagic fever, the effects of ribavirin on platelet function were measured in rhesus monkeys after daily injections of 100 mg/kg IM for 14 days. Drug administration led to a significant increase in platelet count associated with megakaryocyte hyperplasia but had no effect on aggregation of platelet-rich plasma (PRP) in response to either collagen (1.6 μg/ml) or ADP (10 μM/ml). Aggregation in whole blood was also unaffected. Addition of ribavirin to human PRP in concentrations up to 0.5 mg/ml had no effect on aggregation in response to collagen, ADP, or epinephrine (5 μg/ml). Preliminary data from Chinese patients treated with ribavirin for hemorrhagic fever with renal syndrome also reveal no evidence of drug-induced platelet dysfunction as indicated by normal aggregation and release reactions to collagen (3 μg/ml) and ADP (10 μM/ml). Bone marrow studies of megakaryocyte number and ploidy are presently underway to further characterize drug-associated thrombocytosis
APA, Harvard, Vancouver, ISO, and other styles
7

Starnes, Joseph R., Robert J. Samuels, Donald Grant, Emily Engel, Jeffrey G. Shaffer, John S. Schieffelin, and Troy Moon. "Diagnosis and Management of Lassa Fever Among Children in Eastern Province, Sierra Leone: A 7-year Retrospective Analysis." In AAP National Conference & Exhibition Meeting Abstracts. American Academy of Pediatrics, 2021. http://dx.doi.org/10.1542/peds.147.3_meetingabstract.268.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Lassa fever"

1

Frame, John D. Lassa Fever Immune Plasma. Fort Belvoir, VA: Defense Technical Information Center, October 1990. http://dx.doi.org/10.21236/ada232145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Poznansky, Mark, Timothy Brauns, and Pierre Leblanc. Rapid Generation and Testing of a Lassa Fever Vaccine Using VaxCelerate Platform. Fort Belvoir, VA: Defense Technical Information Center, August 2014. http://dx.doi.org/10.21236/ada613596.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Lassa fever' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography